利钠肽指导治疗对射血分数降低的心力衰竭高危患者住院或心血管死亡的影响:一项随机临床试验
GUIDE-IT研究是一项在美加45个中心开展的随机多中心临床试验,计划纳入1100例射血分数≤40%、近期利钠肽升高且有HF事件史的心力衰竭患者,因无效提前终止时纳入894例。NT-proBNP指导治疗组与常规治疗组的主要终点(首次HF住院或心血管死亡)发生率均为37%(校正HR 0.98,95%CI 0.79-1.22,P=0.88),心血管死亡率分别为12%和13%(HR 0.94,95%CI 0.65-1.37,P=0.75),所有次要终点及NT-proBNP降幅均无显著差异。
要点
- NT-proBNP指导治疗组主要终点发生率为37%,常规治疗组为37%(校正HR 0.98,P=0.88)。
- 心血管死亡率在NT-proBNP指导组为12%,常规治疗组为13%(HR 0.94,P=0.75)。
- 所有次要终点及NT-proBNP降幅在两组间均无显著差异。
核心结论
- 在射血分数降低的心力衰竭高危患者中,NT-proBNP指导治疗策略在改善结局方面并不优于常规治疗策略。
研究设计与样本
- GUIDE-IT研究是一项随机多中心临床试验,于2013年1月16日至2016年9月20日在美国和加拿大的45个临床中心开展。
- 研究计划随机纳入1100例射血分数≤40%、既往30天内利钠肽水平升高且有既往心力衰竭事件(心力衰竭住院或等效事件)史的心力衰竭患者。
- 因无效,数据与安全监察委员会建议终止研究时,已纳入894例患者(中位年龄63岁;女性286例,占32%),中位随访15个月。
- 患者随机接受NT-proBNP指导治疗策略(n=446)或常规治疗(n=448)。
主要发现
- 主要终点(首次心力衰竭住院或心血管死亡的复合终点)在生物标志物指导组发生164例(37%),在常规治疗组发生164例(37%)(校正HR 0.98;95%CI 0.79-1.22;P=0.88)。
- 心血管死亡率在生物标志物指导组为12%(n=53),在常规治疗组为13%(n=57)(HR 0.94;95%CI 0.65-1.37;P=0.75)。
- 所有次要终点及达到的NT-proBNP水平降幅在两组间均无显著差异。
关键数值与推荐
- NT-proBNP指导治疗组的目标为NT-proBNP低于1000 pg/mL。
- 常规治疗组按照已发表指南进行心力衰竭管理,重点滴定已证实有效的神经激素治疗,不鼓励连续测量NT-proBNP。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因无效被数据与安全监察委员会建议提前终止,实际纳入894例,低于计划的1100例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with inconsistent results. OBJECTIVE: To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical outcomes vs usual care in high-risk patients with HF and reduced ejection fraction (HFrEF). DESIGN, SETTINGS, AND PARTICIPANTS: The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study was a randomized multicenter clinical trial conducted between January 16, 2013, and September 20, 2016, at 45 clinical sites in the United States and Canada. This study planned to randomize 1100 patients with HFrEF (ejection fraction ≤40%), elevated natriuretic peptide levels within the prior 30 days, and a history of a prior HF event (HF hospitalization or equivalent) to either an NT-proBNP-guided strategy or usual care. INTERVENTIONS: Patients were randomized to either an NT-proBNP-guided strategy or usual care. Patients randomized to the guided strategy (n = 446) had HF therapy titrated with the goal of achieving a target NT-proBNP of less than 1000 pg/mL. Patients randomized to usual care (n = 448) had HF care in accordance with published guidelines, with emphasis on titration of proven neurohormonal therapies for HF. Serial measurement of NT-proBNP testing was discouraged in the usual care group. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of time-to-first HF hospitalization or cardiovascular mortality. Prespecified secondary end points included all-cause mortality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular reasons, the individual components on the primary end point, and adverse events. RESULTS: The data and safety monitoring board recommended stopping the study for futility when 894 (median age, 63 years; 286 [32%] women) of the planned 1100 patients had been enrolled with follow-up for a median of 15 months. The primary end point occurred in 164 patients (37%) in the biomarker-guided group and 164 patients (37%) in the usual care group (adjusted hazard ratio [HR], 0.98; 95% CI, 0.79-1.22; P = .88). Cardiovascular mortality was 12% (n = 53) in the biomarker-guided group and 13% (n = 57) in the usual care group (HR, 0.94; 95% CI; 0.65-1.37; P = .75). None of the secondary end points nor the decreases in the NT-proBNP levels achieved differed significantly between groups. CONCLUSIONS AND RELEVANCE: In high-risk patients with HFrEF, a strategy of NT-proBNP-guided therapy was not more effective than a usual care strategy in improving outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01685840.
引用
- Felker GM, Anstrom KJ, Adams KF, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017. PMID: 28829876. doi:10.1001/jama.2017.10565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。